<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reduced-intensity allogeneic transplantations for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients have been limited by significant <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), treatment-related mortality, and disease relapse </plain></SENT>
<SENT sid="1" pm="."><plain>We treated 18 MDS patients ineligible for standard allogeneic transplantation with a preparative regimen of photopheresis day -7 and -6, pentostatin 4 mg/m(2) by continuous infusion day -5 and -4, and total body irradiation 600 cGy in 3 fractions day -3 and -2, followed by allogeneic stem cell infusion from 6/6 or 5/6 HLA-matched related donors or 6/6 HLA-matched unrelated donors </plain></SENT>
<SENT sid="2" pm="."><plain>GVHD prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and a short course of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The median age was 54 years (range, 30-70 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Diagnoses included <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (n = 2), <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (n = 2), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (n = 10), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (n = 3), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 1) </plain></SENT>
<SENT sid="5" pm="."><plain>Sixteen of 18 patients developed full donor chimerism with no day +100 transplant-related mortality </plain></SENT>
<SENT sid="6" pm="."><plain>Grade II to IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD developed in 19% and 18% of patients, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Disease relapse occurred in 2 patients </plain></SENT>
<SENT sid="8" pm="."><plain>At a median follow-up of 14 months (range, 1-35 months), the 1-year failure-free and overall survival were 64% and 65%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Our photopheresis and pentostatin-based reduced-intensity preparative regimen for allogeneic bone marrow transplantation in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients achieves successful donor engraftment and disease remission with less transplant toxicity and grade II to IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD </plain></SENT>
</text></document>